48,830
edits
Line 33: | Line 33: | ||
*t(8;21)(q22;q22).<ref>{{Cite journal | last1 = Berger | first1 = R. | title = Translocation t(8;21)(q22;q22): cytogenetics and molecular biology. | journal = Nouv Rev Fr Hematol | volume = 36 Suppl 1 | issue = | pages = S67-9 | month = | year = 1994 | doi = | PMID = 8177719 }}</ref> | *t(8;21)(q22;q22).<ref>{{Cite journal | last1 = Berger | first1 = R. | title = Translocation t(8;21)(q22;q22): cytogenetics and molecular biology. | journal = Nouv Rev Fr Hematol | volume = 36 Suppl 1 | issue = | pages = S67-9 | month = | year = 1994 | doi = | PMID = 8177719 }}</ref> | ||
IHC | ===IHC=== | ||
*CD34+, CD13+, MPO+ (cytoplasm), CD33+ (weak). | *CD34+, CD13+, MPO+ (cytoplasm), CD33+ (weak). | ||
*[[CD56]]+, CD117+. | *[[CD56]]+, CD117+. | ||
**Usu. assoc. with a bad prognosis. | **Usu. assoc. with a bad prognosis. | ||
Flow cytometry | ===Flow cytometry=== | ||
*CD19+, PAX5+, CD79a +/-. | *CD19+, PAX5+, CD79a +/-. | ||
Line 50: | Line 50: | ||
*Associated with [[myeloid sarcoma]]. | *Associated with [[myeloid sarcoma]]. | ||
Microscopic | ===Microscopic=== | ||
*Blast count usu. ~20% (low). | *Blast count usu. ~20% (low). | ||
*Eosinophilic granules. | *Eosinophilic granules. | ||
**Used to be classified as "M4" with eosinophilia. | **Used to be classified as "M4" with eosinophilia. | ||
IHC | ===IHC=== | ||
*CD2+ -- common. | *CD2+ -- common. | ||
edits